



Press Release

Louvain-la-Neuve, Belgium, and Lalaye, France – April 23, 2014

PROTON THERAPY: THE GLOBAL MARKET REACHED \$630 MILLION IN 2013

MEDraysintell, the expert in strategic intelligence for the medical radiation industry, publishes today a white paper providing some information about the global Proton Therapy market in 2013-2014.

The world Proton Therapy market size in 2013 is valued at US\$ 630 million, yet 2013 was not the year of proton therapy that we hoped for. A few things have been delayed by a year or so.

In 2014, the market is expected to grow by about 30%, driven by the expected opening of 18 new particle therapy facilities in 7 countries for a total of 41 treatment rooms. 2014 will be the first year in the history of particle therapy to see so many new centers opening their doors. In comparison, the year 2012 saw only two facilities starting to treat patients in a total of eight treatment rooms.

Proton therapy remains a niche market, it has been subject to substantial interests in the past decade and it is expected that there will be a significant growth in proton treatment facilities around the world in the foreseeable future. The race is now on to develop smaller and cheaper PT systems. Almost all proton therapy vendors already have or are developing a compact PT system.

To receive this free two pages white paper, just send your contact details at peg@medraysintell.com

About MEDraysintell

Medical Radiation Strategic Intelligence Experts

Bringing value to Businesses and Investors!

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in radiotherapy, particle therapy and nuclear medicine. We aim to form an international team of experts in the field of Medical Radiation to provide Strategic Intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the markets and the competitive environment, as well as the potential of mergers and acquisitions (M&A) and technology development. MEDraysintell wants to support in their decisional process manufacturers of radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment and software, as well as investors interested in this industry.

www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-mail : rz@medraysintell.com
Mobile : +33 6 82 80 06 00